价格

Truebinding, Inc.

ACTIVE

25565 Whitesell St, 加利福尼亚州圣马特奥县, California, 美国www.truebinding.comHolding51–100 名员工成立于: 2015-01-01

概览

试验阶段分布

阶段

试验数

占比

1 期

42.9%

2 期

42.9%

试验状态分布

Available

14.3%

已完成

28.6%

招募中

14.3%

终止

14.3%

撤回

28.6%

药物批准

暂无批准数据

资讯

Investigational Monoclonal Antibody TB006 Shows Promise in Reversing Alzheimer's Disease Through Galectin-3 Targeting

- TB006, an investigational monoclonal antibody developed by TrueBinding, Inc., targets galectin-3 protein and has shown potential to reverse Alzheimer's disease in studies. - The drug is currently available through the FDA's Expanded Access Program for eligible Alzheimer's patients with no other treatment options, with only seven doctors in Texas authorized to administer it. - TB006 is also being investigated for treating Parkinson's disease and Autism Spectrum Disorder, with reported improvements in patients with these conditions. - The treatment costs $5,000 per month for four monthly treatments totaling $20,000, though insurance coverage is hoped for in the future.

May 29, 2025

返回机构列表

Truebinding, Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（7）

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

TB006 Expanded Access (EA) Compassionate Use

药物批准

资讯

Investigational Monoclonal Antibody TB006 Shows Promise in Reversing Alzheimer's Disease Through Galectin-3 Targeting